On 24 June 2026, TORTUS became the first ambient voice technology (AVT) to achieve UKCA Class IIa certification, independently assessed by Scarlet (UK Approved Body 8536). The substance of the change is this: TORTUS has moved from a self-declared Class I device to one whose higher-risk intended purpose, now described as a clinical decision-support medical device, has been externally validated by a UK Approved Body. That is a meaningful step up in regulatory assurance. It is not, however, a claim that the tool replaces clinical judgement. Here is what actually changed, and what did not.
Key takeaways
- TORTUS is the first AVT certified UKCA Class IIa, assessed by Scarlet (UK Approved Body 8536), on 24 June 2026.
- Class I is self-declared by the manufacturer; Class IIa requires independent conformity assessment by an Approved Body.
- The certified intended purpose now covers higher-risk functions, but human verification of every output remains required.
- TORTUS reports a substantial compliance effort to reach this point, including ISO 13485 and multiple external audits.
- For practices already using it, local governance, consent and output-checking obligations do not go away.
What was announced, and who certified it?
TORTUS announced that its platform has been certified as a UKCA Class IIa medical device by Scarlet, a UK Approved Body (number 8536). It is the first ambient voice technology to reach this classification under the UK's own regime. TORTUS had previously been the first ambient scribe registered as a Class I medical device with the MHRA, and it has been selected into Phase 2 of the MHRA's AI Airlock programme, which is specifically examining where documentation tools cross into higher-risk, decision-support territory. This certification is the next step along that path.
Class I self-declaration versus Class IIa validation, in plain terms
The distinction is who checks the work. A Class I medical device is self-declared: the manufacturer assesses its own conformity, holds the technical documentation, and registers with the MHRA, without an external body reviewing the file. A Class IIa device cannot be self-declared. It requires an independent Approved Body to carry out a conformity assessment, auditing the manufacturer's quality management system and examining technical documentation, before a UKCA mark and the Approved Body's identification number can be applied. So the move from Class I to Class IIa is the move from "the company says it meets the standard" to "an independent body has assessed that it does," for a higher-risk intended purpose.
What does the certified intended purpose cover, and what does it not?
This is the part to read carefully. For ambient voice tools, Class IIa is triggered when the software goes beyond transcription and summarisation into functions such as coding or decision support, which carry more risk. TORTUS being certified as a clinical decision-support device reflects that those higher-risk functions are now within its certified intended purpose, validated at Class IIa.
What it does not mean is that the tool diagnoses autonomously or replaces the clinician. TORTUS's own model keeps a clinician in the loop, with outputs approved before they enter the record. The certificate defines a specific intended purpose and scope; it is not a general seal that covers any use. The practical rule for clinicians is unchanged: use the tool within its stated intended purpose, and verify its output.
The scale of the lift
TORTUS describes a considerable compliance effort to reach Class IIa. According to the company, the process ran across roughly two years and involved four external audits, ISO 13485 quality-management certification, and in the region of 136 controlled documents. These are the company's own figures for its process, and they are worth reporting because they illustrate the point: Class IIa is a substantially higher bar than Class I self-declaration, which is why it has taken the market this long to produce a first. TORTUS also reports scale behind the submission, including use across around 2.5 million consultations and participation in one of Europe's largest ambient-voice evaluations.
What changes tomorrow for a Trust or GP practice already using it, and what does not?
If your practice already uses TORTUS, day-to-day use does not suddenly change, and neither do your responsibilities. The certification strengthens the assurance position and clarifies where clinical-safety judgement has been externally validated, which can simplify parts of a local business case. But the standing obligations remain: complete your DTAC and DSPT requirements, maintain patient consent and information-governance processes, keep a clinician reviewing and approving every output before it enters the record, and continue local incident reporting. Certification is not a guarantee of zero error, which is exactly why post-market surveillance and human verification still matter. What changes is the strength of the assurance underneath the tool; what does not change is the need to use it safely.
Where a guideline-grounded reference sits alongside a scribe
It is worth being clear about categories, because a scribe and a clinical reference tool do different jobs. A scribe documents the consultation; it does not tell you whether the management plan is right. A guideline-grounded reference tool does the opposite: it helps a clinician check what current UK guidance recommends. The two are complementary rather than competing. Ask iatroX, for example, is a free, UK-guideline-grounded clinical reference tool (itself a UKCA Class I, MHRA-registered device for reference and education), which a clinician might use to verify a plan that a scribe has helped document. Neither replaces the clinician; each supports a different part of the workflow. For more on the scribe landscape, see our guide to AI medical scribes in UK primary care, and for the regime nuance, our piece on UKCA versus EU MDR Class IIa.
Frequently asked questions
What did TORTUS achieve on 24 June 2026? It became the first ambient voice technology certified as a UKCA Class IIa medical device, independently assessed by Scarlet (UK Approved Body 8536), moving up from self-declared Class I.
What is the difference between Class I and Class IIa? Class I is self-declared by the manufacturer. Class IIa requires an independent Approved Body to assess the quality management system and technical documentation before certification. It applies to higher-risk intended purposes.
Does Class IIa mean the tool can diagnose on its own? No. It means a higher-risk intended purpose, including decision-support functions, has been externally validated. A clinician still reviews and approves outputs, and the tool works within its stated intended purpose.
Do we need to change how we use TORTUS now? Not in daily use. Your local obligations continue: DTAC and DSPT, consent and information governance, human verification of every output, and incident reporting. Certification strengthens assurance but does not remove these.
Why has it taken so long for a Class IIa AVT to appear? Because Class IIa is a much higher bar than Class I self-declaration. TORTUS reports a roughly two-year effort with external audits, ISO 13485 and extensive documentation, which illustrates the size of the step.